{"nctId":"NCT00010803","briefTitle":"Ginkgo Biloba Prevention Trial in Older Individuals","startDateStruct":{"date":"2000-10"},"conditions":["Dementia","Alzheimer's Disease"],"count":3069,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Ginkgo biloba","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ginkgo biloba"]}],"interventions":[{"name":"Ginkgo biloba","otherNames":["EGb761"]},{"name":"Placebo","otherNames":["Identical appearance as Ginkgo biloba pill"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Non-demented participants\n* Willing to participate in a seven-year follow-up trial of Ginkgo Biloba\n* English is their usual language\n* Willing informant who has frequent contact with the participant\n\nExclusion Criteria:\n\n* Currently on anticoagulant therapy\n* Cancer diagnosed and treated within the past two years (except for skin cancer)\n* Participant with class III - IV congestive heart failure\n* Currently being treated with psychopharmacological drugs for depression\n* Hospitalized for depression within the last year\n* Taking Aricept (or similar agents) for cognitive problems or dementia\n* Baseline blood creatinine \\>2\n* Baseline SGGT is a marker of liver function (3 x normal\\>or=90 IU)\n* Baseline hematocrit\\<30\n* Baseline white blood count\\>or=15,000","healthyVolunteers":true,"sex":"ALL","minimumAge":"75 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Incident Dementia","description":"All cause dementia based on DSM-IV criteria as determined by an expert panel of clinicians using an adjudication process. A full neuropsychological battery was administered annually, or at 6 month visit if there was a diagnosis of dementia or initiation of medication for dementia by private physician, or change in Modified Mini Mental State Exam (3MSE), Clinical Dementia Rating (CDR), or Alzheimer Disease Assessment Scale (ADAS-Cog). Decline on tests scores based on an algorithm resulted in a neurological exam and brain imaging. These data were used in the adjudication process.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"277","spread":null},{"groupId":"OG001","value":"246","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Cardiovascular Disease or Mortality","description":"Myocardial infarction (MI), angina, stroke (CVA), transient ischemic attack (TIA), combined coronary heart disease (CHD) (MI/angina), combined cerebrovascular (CVA/TIA), peripheral vascular disease, and mortality","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"197","spread":null},{"groupId":"OG001","value":"188","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":null},{"groupId":"OG001","value":"122","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"154","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression of Cognitive Decline in Standardized Z-score Scale. Higher Z-scores Indicate Worse Performance.","description":"Rate of annual change by cognitive domain in standardized Z-score scale. Higher Z-scores indicate worse performance. Best score = -2.0 Z-score change per year (improvement); worse score = 2.0 Z-score change per year (decline).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.069","spread":null},{"groupId":"OG001","value":"0.071","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.043","spread":null},{"groupId":"OG001","value":"0.041","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.043","spread":null},{"groupId":"OG001","value":"0.048","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.107","spread":null},{"groupId":"OG001","value":"0.118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.045","spread":null},{"groupId":"OG001","value":"0.041","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.092","spread":null},{"groupId":"OG001","value":"0.089","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1000,"n":1545},"commonTop":["All adverse events","Self-reported non-hospitalized symptom collected every 6 months","non-hospitalized self-reported symptom"]}}}